A Phase II Study of Radiation Therapy Concurrent With Cetuximab in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Do Not Qualify For Standard Chemotherapy Due To Age>70 Or Co-Morbidities
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor Response to Concurrent Cetuximab and Radiation Therapy
Determine changes in tumor Epidermal Growth Factor Receptor (EGFR), Phosphorylated Epidermal Growth Factor Receptor (pEGFR), downstream signaling, and novel phosphoproteins following a loading dose of cetuximab in patients who are poor candidates for chemoradiation (age ≥70 years or with significant co-morbidities) and are therefore treated with cetuximab and radiation.
Shruti Jolly, MD
University of Michigan Cancer Center
United States: Institutional Review Board
|The University of Michigan Comprehensive Cancer Center||Ann Arbor, Michigan 48109|